

# CONTENTS

	PREFACE	XXVII
	ACKNOWLEDGMENTS	XXXIII
<b>CHAPTER 1</b>	<b>INTRODUCTION AND OVERVIEW</b>	<b>1</b>
1.1	HEALTH ECONOMICS AS A FIELD OF INQUIRY	2
	THE IMPORTANCE OF HEALTH ECONOMICS	2
	THE GROWTH OF HEALTH ECONOMICS	3
1.2	FACTORS ACCOUNTING FOR THE GROWTH OF HEALTH ECONOMICS	4
	IMPROVEMENTS IN HEALTH AND LONGEVITY	4
	EXPANSION OF HEALTH SECTORS	8
1.3	IMPORTANT INSTITUTIONAL FEATURES OF HEALTH CARE	10
	HEALTH INSURANCE	11
	EXTERNALITIES AND GOVERNMENT INTERVENTION IN HEALTH CARE SERVICES PROVISION	13
	ASYMMETRIC INFORMATION BETWEEN CONSUMERS AND SUPPLIERS OF HEALTH CARE, AND THE INSTITUTIONAL RESPONSES	15
1.4	GOVERNMENT INTERVENTION IN HEALTH CARE MARKETS	16
	GOVERNMENT'S ROLES IN ACHIEVING AN EQUITABLE DISTRIBUTION OF RESOURCES	16
	THE EQUITY-EFFICIENCY QUANDARY AND GOVERNMENT'S ROLE	18
	GOVERNMENT'S ROLE IN CORRECTING MARKET FAILURES	20
1.5	THE BOOK'S FOUR PARTS: A ROAD MAP	20
	STRUCTURE OF THE BOOK	20
	PART I DEMAND FOR HEALTH, HEALTH CARE SERVICES, AND INSURANCE	22
	PART II SUPPLY OF HEALTH CARE SERVICES AND INSURANCE	24
	PART III MARKET STRUCTURE IN THE HEALTH CARE SECTOR	28
	PART IV PERFORMANCE OF THE HEALTH CARE SECTOR: POSITIVE AND NORMATIVE ASPECTS	30
1.6	CONCLUSION	32
	KEY CONCEPTS	32
	REVIEW AND DISCUSSION QUESTIONS	33

	EXERCISES	33
	ONLINE SUPPLEMENTAL MATERIAL	34
	SUPPLEMENTAL READINGS	34
	REFERENCES	34
<b>PART I</b>	<b>DEMAND FOR HEALTH, HEALTH CARE, AND INSURANCE</b>	<b>37</b>
<b>CHAPTER 2</b>	<b>HEALTH AND HEALTH BEHAVIORS</b>	<b>39</b>
	2.1 RATIONALITY AND OTHER ECONOMIC ASSUMPTIONS	40
	2.2 HEALTH PRODUCTION FUNCTIONS	43
	THE CONCEPT	43
	HEALTH STOCKS AND FLOWS	45
	2.3 THE DEMAND FOR HEALTH: HEALTH AS A CAPITAL STOCK	45
	EVOLUTION OF A PERSON'S HEALTH OVER TIME	45
	DEMAND FOR HEALTH AND FOR MEDICAL CARE	47
	PREDICTIONS OF THE GROSSMAN MODEL	52
	A Reduction in the Price of Medical Care	52
	An Increase in the Individual's Wage Rate	52
	An Increase in the Individual's Age	52
	An Increase in the Individual's Educational Attainment	54
	2.4 MEASURING HEALTH CAPITAL	55
	MORTALITY	56
	QUALITY-OF-LIFE RATING SCALES	56
	QUALITY OF LIFE DERIVED FROM TRADE-OFF QUESTIONS	57
	2.5 ADDING UNCERTAINTY: DECISION TREES, BACKWARD INDUCTION, AND DECISION MAKING UNDER UNCERTAINTY	59
	A REALISTIC APPLICATION: A PEDIATRICIAN'S DECISION ABOUT ORDERING A THROAT CULTURE	60
	ERRORS IN DIAGNOSTIC TESTS	62
	2.6 CONSUMER CHOICES ABOUT HEALTH BEHAVIORS: A GENERAL FRAMEWORK	63
	UNHEALTHY BEHAVIORS	63
	THE CONCEPT OF PRESENT VALUE	64
	FUNDAMENTAL UNDERLYING ASSUMPTIONS	64
	Assumptions: Rational, Forward-Looking, and Time Consistency Described	64

EX ANTE EXPECTATIONS AND DECISIONS, EX POST REALIZATIONS, AND REVISING EXPECTATIONS FROM LEARNING	66
IS THE ECONOMIC FRAMEWORK OF HEALTH BEHAVIOR DECISION MAKING PLAUSIBLE?	67
ECONOMIC EVIDENCE ON HEALTH BEHAVIORS AND PUBLIC POLICY IMPLICATIONS	67
2.7 FRONTIER ISSUES: THE BEHAVIORAL ECONOMICS CRITIQUE—THEORY AND EVIDENCE	69
2.8 SUMMARY AND CONCLUSIONS	71
KEY CONCEPTS	72
REVIEW AND DISCUSSION QUESTIONS	72
EXERCISES	73
ONLINE SUPPLEMENTAL MATERIAL	77
SUPPLEMENTAL READINGS	77
REFERENCES	78
<b>CHAPTER 3 DEMAND FOR HEALTH CARE SERVICES</b>	<b>81</b>
3.1 BASIC ECONOMIC CONCEPTS OF DEMAND	83
3.2 DEMAND IN THE CONTEXT OF HEALTH INSURANCE COVERAGE	85
3.3 THE CONCEPT OF TIME PRICE	92
3.4 EMPIRICAL STUDIES OF DEMAND	95
DATA USED IN DEMAND STUDIES	95
Observational Data	95
Randomized Controlled Trials	96
Natural Experiments	98
THE RAND HEALTH INSURANCE EXPERIMENT	98
The Research Issues	98
HIE Study Design	100
HIE Results	101
Effects of Deductibles	104
COST SHARING: GREATER EFFECT ON DEMAND FOR LOW-INCOME THAN FOR HIGH-INCOME FAMILIES?	105
INCOME EFFECTS ON DEMAND FOR CARE	105
EFFECTS OF CAPITATION ON USE OF SERVICES	107
The Oregon Experiment	109

	Capitation in a Low-Income Country	110
	OTHER EMPIRICAL EVIDENCE ON THE EFFECT OF HEALTH INSURANCE ON THE USE OF PERSONAL HEALTH CARE SERVICES	111
	Emergency Department and Hospital Inpatient Use by Young Adults	111
	Prescription Drugs	111
	Empirical Evidence on the Effects of Health Insurance on Demand in Low- and Middle-Income Countries	113
	DOES HEALTH INSURANCE IMPROVE HEALTH?	114
3.5	WELFARE ANALYSIS	115
3.6	OTHER DETERMINANTS OF DEMAND FOR PERSONAL HEALTH CARE SERVICES	118
3.7	SUMMARY AND CONCLUSIONS	119
	KEY CONCEPTS	120
	REVIEW AND DISCUSSION QUESTIONS	121
	EXERCISES	122
	ONLINE SUPPLEMENTAL MATERIAL	124
	SUPPLEMENTAL READINGS	124
	REFERENCES	125
<b>CHAPTER 4</b>	<b>DEMAND FOR PRIVATE HEALTH INSURANCE</b>	<b>127</b>
4.1	RELATIONSHIPS AMONG HEALTH, HEALTH INSURANCE, AND THE USE OF PERSONAL HEALTH CARE SERVICES	128
4.2	INSURANCE CONCEPTS AND TERMINOLOGY	130
	FIRST-PARTY AND THIRD-PARTY INSURANCE	130
	PECUNIARY AND NONPECUNIARY LOSS	131
	THE PRICE OF INSURANCE	131
4.3	DIMINISHING MARGINAL UTILITY OF WEALTH AND THE DEMAND FOR INSURANCE	133
	UTILITY OF WEALTH	133
	EXPECTED UTILITY	134
4.4	MODEL OF DEMAND FOR INSURANCE	136
	THE BASIC MODEL	136
	EFFECTS OF SHIFTS IN THE UTILITY FUNCTION, CHANGES IN $\theta$ , AND CHANGES IN $L$ ON THE DECISION TO PURCHASE INSURANCE	138
	Shifts in the Utility Function	138
	Change in Probability of Incurring a Loss (Becoming Sick)	139

	Change in the Magnitude of the Loss Conditional on Incurring a Loss (Becoming Sick)	139
	THE RISK-LOVER CASE	139
	IMPLICATIONS OF THEORY: DETERMINANTS OF DEMAND FOR INSURANCE	140
	THE PREMIUM OF A HEALTH INSURANCE POLICY	141
4.5	EMPIRICAL ISSUES	142
	WHY DO THE PROBABILITY AND MAGNITUDE OF THE LOSS VARY?	142
	WHY INCOME AFFECTS DEMAND FOR INSURANCE	142
	HOW ADVERSE SELECTION MAY ARISE IN HEALTH INSURANCE MARKETS	144
	ADVERSE SELECTION AND UNRAVELING IN INSURANCE MARKETS	147
	ADVERSE SELECTION AND UNRAVELING: THE CASE OF HARVARD UNIVERSITY	151
4.6	EMPIRICAL EVIDENCE ON ADVERSE SELECTION IN PRIVATE HEALTH INSURANCE MARKETS	154
4.7	“RISK ADJUSTMENT” AND ADVERSE AND PREFERRED RISK SELECTION	156
4.8	SUMMARY AND CONCLUSIONS	159
	KEY CONCEPTS	161
	REVIEW AND DISCUSSION QUESTIONS	161
	EXERCISES	162
	ONLINE SUPPLEMENTAL MATERIAL	163
	SUPPLEMENTAL READINGS	163
	REFERENCES	164
<b>PART II</b>	<b>SUPPLY OF HEALTH CARE SERVICES AND INSURANCE</b>	<b>167</b>
<b>CHAPTER 5</b>	<b>THE MARKET FOR PHYSICIANS’ SERVICES</b>	<b>169</b>
5.1	MEDICAL SCHOOL CAPACITY AND CONCEPTS OF PHYSICIAN SHORTAGE AND SURPLUS	170
5.2	PHYSICIAN SUPPLY IN THE LONG RUN	172
	CHOICE OF MEDICINE AS A CAREER	172
	PHYSICIAN CHOICE OF SPECIALTY	177
	Concept of Present Value	177
	Concept of Internal Rate of Return	178
	PHYSICIAN GEOGRAPHIC LOCATION DECISIONS	182
	THE ECONOMICS OF PHYSICIAN GROUP PRACTICE	183

	Economies of Scale and Scope	183
	Referrals	184
	Coverage of Patients	184
	Reduction in Earnings Fluctuations	184
	Empirical Evidence	185
5.3	PHYSICIANS' SHORT-RUN DECISIONS	186
	OVERVIEW	186
	RECONCILING STYLIZED FACTS OF THE PHYSICIANS' SERVICES MARKET WITH STANDARD ECONOMIC MODELS	190
	Why the Demand Curve Facing the Individual Physician May Be Downward Sloping	190
	Stylized Facts and Standard Economic Models: Three Points	192
5.4	PRICE DISCRIMINATION	196
	BACKGROUND	196
	THEORY	197
	Empirical Evidence	200
5.5	PHYSICIAN SERVICES' MARKETS WHEN FEES ARE SET BY PHYSICIAN-INSURER BARGAINING	202
5.6	SUMMARY AND CONCLUSIONS	203
	KEY CONCEPTS	204
	REVIEW AND DISCUSSION QUESTIONS	204
	EXERCISES	206
	ONLINE SUPPLEMENTAL MATERIAL	208
	SUPPLEMENTAL READINGS	208
	REFERENCES	209
<b>CHAPTER 6</b>	<b>HOSPITALS</b>	<b>211</b>
6.1	CONTEXT	212
6.2	ALTERNATIVE MODELS OF HOSPITAL BEHAVIOR	213
	THE PROFIT-MAXIMIZING HOSPITAL: THE BASE CASE	213
	A MODEL OF A PRIVATE NOT-FOR-PROFIT HOSPITAL	216
	The Model's Basics	216
	Effects of Exogenous Changes in Wage Rates, Population Size, Fraction of Persons with Health Insurance Coverage, and Subsidies of Hospitals	220
	Summing Up	220

6.3	HOSPITAL OWNERSHIP AND PERFORMANCE	221
	WHY ARE FOR-PROFIT HOSPITALS A MINORITY?	221
	Fiduciary Relationships and Complex Output	221
	Noncontractible Quality	222
	Public Goods	223
	Implicit Subsidies	223
	Explicit Subsidies	224
	Cartels	224
	Low Profits	226
	EMPIRICAL EVIDENCE ON HOSPITAL OWNERSHIP AND PERFORMANCE	226
	Allegations against For-Profit Hospitals	226
	Empirical Analysis of the Effects of Ownership on Hospital Performance	227
	Reviews of the Literature on the Effects of Ownership on Hospital Performance	229
6.4	REGULATION OF HOSPITALS	230
	CONTEXT	230
	RETROSPECTIVE COST REIMBURSEMENT	230
	REGULATORY RESPONSES	234
	Entry Regulation	234
	Price-Revenue Regulation and Prospective Payment	239
6.5	AN ALTERNATIVE TO REGULATING HOSPITALS: INCREASING COMPETITION AMONG HOSPITALS	244
	DESCRIPTION	244
	EMPIRICAL EVIDENCE ON THE EFFECTS OF COMPETITION UNDER THE NEW REGIME	245
	EMPIRICAL EVIDENCE ON THE EFFECTS OF INCREASED COMPETITION ON HOSPITAL PRICES AND QUALITY	249
6.6	SUMMARY AND CONCLUSIONS	251
	KEY CONCEPTS	252
	REVIEW AND DISCUSSION QUESTIONS	253
	EXERCISES	253
	ONLINE SUPPLEMENTAL MATERIAL	256
	SUPPLEMENTAL READINGS	256
	REFERENCES	257

<b>CHAPTER 7</b>	<b>QUALITY OF CARE AND MEDICAL MALPRACTICE</b>	<b>261</b>
7.1	MARKETS AND MARKET FAILURE	261
7.2	CHARACTERISTICS OF HEALTH CARE QUALITY	265
	HOW ECONOMISTS VIEW QUALITY	265
	HOW THE QUALITY OF PERSONAL HEALTH CARE SERVICES IS MEASURED	266
7.3	ADVERSE EVENTS AND NEGLIGENT INJURIES	269
	THE ISSUES	269
	HOW THE ESTIMATES OF ADVERSE OUTCOMES WERE GENERATED	270
	THE QUALITY OF THE ESTIMATES	270
	DO OBSERVED RATES OF MEDICAL ERRORS AND ADVERSE OUTCOMES REPRESENT A MARKET FAILURE JUSTIFYING GOVERNMENT OR OTHER INTERVENTION?	272
7.4	SUPPLY-SIDE QUALITY-OF-CARE SAFEGUARDS AND GOVERNMENT OVERSIGHT AND REGULATION	272
	OVERVIEW	272
	PROFESSIONAL NORMS	273
	PEER REVIEW	273
	LICENSURE	274
	CERTIFICATION	274
7.5	MANDATORY ERROR REPORTING	275
	DESCRIPTION	275
	IMPLICATIONS	277
7.6	TORT LAW AS A MECHANISM FOR IMPROVING PATIENT SAFETY AND HEALTH CARE QUALITY	277
	WHY OTHER QUALITY ASSURANCE MECHANISMS MAY FAIL	277
	THE ABCs OF TORT LAW	279
	Tort Law Defined	279
	The Socially Optimal Injury Rate	279
	The Negligence Rule: Only One of Several Alternative Liability Rules	281
	Contracts versus Torts	282
	WHEN THE NEGLIGENCE RULE LEADS PRIVATE PARTIES TO SELECT A SOCIALLY OPTIMAL PRECAUTION LEVEL	284
	TORT LIABILITY UNDER ATTACK	285
7.7	MEDICAL MALPRACTICE	286



	OVERVIEW	286
	MEDICAL CARE MARKET	286
	LEGAL MARKET	288
	7.8 DOES THE THREAT OF MEDICAL MALPRACTICE SUITS DETER IATROGENIC INJURIES?	289
	7.9 SUMMARY AND CONCLUSIONS	295
	KEY CONCEPTS	296
	REVIEW AND DISCUSSION QUESTIONS	296
	EXERCISES	297
	ONLINE SUPPLEMENTAL MATERIAL	300
	SUPPLEMENTAL READINGS	300
	REFERENCES	301
<b>CHAPTER 8</b>	<b>NURSES IN HOSPITAL AND LONG-TERM CARE SERVICES</b>	<b>305</b>
	8.1 LABOR MARKETS FOR NURSES WORLDWIDE	306
	8.2 SUPPLY OF NURSES: TOO MANY OR TOO FEW?	311
	ECONOMIC CONCEPTS OF SURPLUS AND SHORTAGE	311
	ROLE OF PUBLIC REGULATION	315
	ROLE OF MONOPSONY POWER	320
	8.3 EMPIRICAL ESTIMATES OF NURSES' RESPONSE TO A WAGE CHANGE	324
	ARE HOSPITALS MONOPSONISTS IN THE MARKET FOR NURSES?	324
	OTHER EMPIRICAL EVIDENCE ON NURSES' LABOR SUPPLY	325
	8.4 NONWAGE DETERMINANTS OF THE NURSE LABOR SUPPLY	329
	8.5 NURSES IN THE PRODUCTION OF HOSPITAL SERVICES	331
	DO HIGHER NURSE-TO-PATIENT RATIOS IMPROVE THE QUALITY OF HOSPITAL CARE?	331
	PUBLIC POLICY RESPONSES	335
	8.6 NURSES IN THE PRODUCTION OF NURSING HOME SERVICES	338
	OVERVIEW	338
	EFFECTS OF ECONOMIC FACTORS ON NURSE STAFFING AND MIX	339
	EFFECTS OF NURSE STAFFING LEVELS AND MIX ON PATIENT OUTCOMES	341
	IMPLICATIONS FOR PUBLIC POLICY	342
	8.7 SUMMARY AND CONCLUSIONS	344

	KEY CONCEPTS	345
	REVIEW AND DISCUSSION QUESTIONS	345
	EXERCISES	346
	ONLINE SUPPLEMENTAL MATERIAL	349
	SUPPLEMENTAL READINGS	349
	REFERENCES	349
<b>CHAPTER 9</b>	<b>PHARMACEUTICAL MANUFACTURERS</b>	<b>353</b>
	9.1 COMPANIES' DECISIONS ABOUT INVESTMENTS IN R&D	354
	BASIC FACTS OF THE PHARMACEUTICAL R&D PROCESS	354
	THE OPTIMAL INVESTMENT DECISION FROM A PHARMACEUTICAL COMPANY'S VANTAGE POINT	356
	INCENTIVES FOR PHARMACEUTICAL INNOVATION	357
	Pull Incentives	357
	Push Incentives	359
	Combinations of Pull and Push Incentives	362
	DISINCENTIVES FOR PHARMACEUTICAL INNOVATION	363
	9.2 PRICING OF NEW DRUGS	367
	RATIONALE FOR PATENTS AND PUBLIC POLICY TRADE-OFFS	367
	PRICING NEW DRUGS: EMPIRICAL EVIDENCE	370
	9.3 ENTRY OF GENERIC DRUGS AND ITS CONSEQUENCES	372
	COMPETITION BETWEEN GENERIC AND BRAND-NAME DRUGS	372
	FACTORS AFFECTING GENERIC COMPETITION	374
	CONSEQUENCES OF GENERIC COMPETITION	376
	9.4 ADVERTISING	377
	COMPANIES' INCENTIVES TO ALLOCATE FUNDS TO MARKETING	378
	COMPOSITION OF PHARMACEUTICAL COMPANY MARKETING	380
	DETAILING AND ITS EFFECTS	381
	DIRECT-TO-CONSUMER ADVERTISING AND ITS EFFECTS	382
	9.5 DEVELOPING NEW DRUGS FOR RARE DISEASES AND DISEASES PREVALENT IN LOW-INCOME COUNTRIES: ENFORCEMENT OF PATENT RIGHTS GLOBALLY	383
	9.6 INTERNATIONAL PRICING	385
	CROSS-NATIONAL PRICE DIFFERENTIALS	385
	THE CONSEQUENCES OF DIFFERENTIAL PRICING	386

	RAMSEY OPTIMAL PRICING	388
	EMPIRICAL EVIDENCE ON RAMSEY PRICING OF PHARMACEUTICALS	390
9.7	DEVELOPING NEW DRUGS: RARE DISEASES AND DISEASES PREVALENT IN LOW-INCOME COUNTRIES	392
	REWARDS AS A SUBSTITUTE FOR PATENTS: OVERVIEW	392
	SPECIFIC PROPOSALS	393
	Advance Purchase Commitments	393
	Optional Rewards Based on Therapeutic Effect	394
	Priority Review Voucher	395
9.8	IMPLEMENTATION OF MEDICARE PART D IN THE UNITED STATES	397
9.9	THE SPECIAL CASES OF VACCINES AND MEDICAL DEVICES	399
	VACCINES	399
	MEDICAL DEVICES	402
9.10	SUMMARY AND CONCLUSIONS	403
	KEY CONCEPTS	405
	REVIEW AND DISCUSSION QUESTIONS	406
	EXERCISES	407
	ONLINE SUPPLEMENTAL MATERIAL	409
	SUPPLEMENTAL READINGS	409
	REFERENCES	410
<b>CHAPTER 10</b>	<b>THE SUPPLY OF PRIVATE HEALTH INSURANCE</b>	<b>415</b>
10.1	THE ABCS OF THE BUSINESS OF INSURANCE	416
	FUNCTIONS OF INSURERS	416
	Risk Bearing	416
	Marketing and Underwriting	417
	Claims Processing	419
	Loss Prevention	419
	MEASURING THE FINANCIAL STRENGTH OF INSURERS: AN INSURER'S INCOME STATEMENT AND BALANCE SHEET	419
	Income Statement	419
	Balance Sheet	420
	INSURERS' CASH FLOW, INCOME FROM INVESTMENTS, AND PREMIUM SETTING	420
	Timing of Insurers' Revenue and Expenses	420
	Investment Income	421

Higher Investment Income Leads to Lower Premiums on the Underwriting Side of an Insurer's Business	421
REINSURANCE	422
UNDERWRITING CYCLES	423
10.2 ARE INSURERS' PREMIUMS AND RETURNS EXCESSIVE?	423
10.3 PRIVATE VERSUS PUBLIC PROVISION OF HEALTH INSURANCE COVERAGE	425
THE CASE FOR AND AGAINST RELYING ON PRIVATE HEALTH INSURANCE FOR PROVISION OF COVERAGE TO A POPULATION	426
10.4 EMPLOYER-BASED PRIVATE HEALTH INSURANCE COVERAGE	430
ADVANTAGES OF EMPLOYER-BASED COVERAGE	430
WHO REALLY PAYS FOR EMPLOYER-BASED HEALTH INSURANCE COVERAGE?	432
10.5 GOVERNMENT REGULATION OF PRIVATE HEALTH INSURANCE	435
RATIONALE FOR GOVERNMENT REGULATION	435
INSURANCE MANDATES: A FORM OF PRIVATE REGULATION OF PRIVATE HEALTH INSURANCE	438
COMMUNITY RATING	442
MANAGED CARE DEFINED	443
THE EFFECT OF MANAGED CARE ON MARKET STRUCTURE AND PROVIDERS' AND PATIENTS' INCENTIVES	447
MANAGED CARE AND HEALTH SYSTEM PERFORMANCE	449
Overview	449
Effects of Managed Care on Spending on Personal Health Care	450
Effects of Managed Care on Diffusion of Technology	452
THE BACKLASH AGAINST MANAGED CARE	455
COMPETITION AMONG PRIVATE INSURERS: ARE HEALTH INSURANCE MARKETS COMPETITIVE?	455
PRIVATE HEALTH INSURANCE AND UNIVERSAL HEALTH INSURANCE COVERAGE	456
10.6 SUMMARY AND CONCLUSIONS	457
KEY CONCEPTS	459
REVIEW AND DISCUSSION QUESTIONS	459
EXERCISES	460
ONLINE SUPPLEMENTAL MATERIAL	462
SUPPLEMENTAL READINGS	462
REFERENCES	462

<b>PART III</b>	<b>MARKET STRUCTURE IN THE HEALTH CARE SECTOR</b>	<b>467</b>
<b>CHAPTER 11</b>	<b>PRIVATE FINANCING OF HEALTH CARE SERVICES</b>	<b>469</b>
	11.1 RATIONALE FOR HEALTH SYSTEMS ANALYSIS	470
	11.2 CLASSIFICATION OF HEALTH CARE SYSTEMS	474
	11.3 CASH SYSTEMS	484
	OVERVIEW	484
	THE INDIAN HEALTH CARE SYSTEM	485
	11.4 THE PRIVATE SYSTEM: THE US EXPERIENCE	487
	BASE CASE: PRIVATE PROVISION AND NO INSURANCE COVERAGE	487
	EVOLUTION OF PRIVATE HEALTH INSURANCE IN THE 1930S AND 1940S	487
	11.5 THE MANAGED COMPETITION MODEL	489
	11.6 COMPARISONS BETWEEN SINGLE- AND MULTIPLE-PAYER SYSTEMS	491
	COST SHIFTING	491
	PATIENT SELECTION	492
	SPILLOVER EFFECTS	493
	11.7 THE PATIENT PROTECTION AND AFFORDABLE CARE ACT IN THE UNITED STATES	494
	KEY PROVISIONS OF THE PATIENT PROTECTION AND AFFORDABLE CARE ACT	494
	THE MASSACHUSETTS EXPERIENCE WITH ACA-TYPE HEALTH REFORM	495
	OTHER EMPIRICAL EVIDENCE POSSIBLY RELATED TO FUTURE EFFECTS OF THE ACA	498
	EARLY EMPIRICAL EVIDENCE ON THE EFFECTS OF THE ACA	499
	11.8 SUMMARY AND CONCLUSIONS	500
	KEY CONCEPTS	502
	REVIEW AND DISCUSSION QUESTIONS	502
	EXERCISES	502
	ONLINE SUPPLEMENTAL MATERIAL	504
	SUPPLEMENTAL READINGS	504
	REFERENCES	504
<b>CHAPTER 12</b>	<b>GOVERNMENT FINANCING AND PRIVATE SUPPLY</b>	<b>509</b>
	12.1 THE ROLE OF GOVERNMENT AS A PAYER: RATIONALE FOR THE PUBLIC PROVISION OF HEALTH INSURANCE	510
	UNIVERSAL COVERAGE, SOCIAL INSURANCE, AND MEANS-TESTED INSURANCE	510
	ARGUMENTS OF ADVOCATES FOR THE PUBLIC PROVISION OF HEALTH INSURANCE	512
	CHOICES IN THE DESIGN OF PUBLIC PAYMENT SYSTEMS	514

12.2 EVOLUTION AND STRUCTURE OF THE PAYMENT SYSTEM: GERMAN STATUTORY HEALTH INSURANCE	522
12.3 EVOLUTION AND STRUCTURE OF THE PAYMENT SYSTEM: THE US MEDICARE PROGRAM	526
BACKGROUND	526
HOSPITAL PAYMENT UNDER MEDICARE: THE MEDICARE PROSPECTIVE PAYMENT SYSTEM	529
PHYSICIAN PAYMENT UNDER MEDICARE: FIXED FEES BASED ON A RESOURCE-BASED RELATIVE VALUE SCALE	530
EFFECTS OF MEDICARE	534
Technological Change	534
Population Subgroups	534
Population Health	536
12.4 EVOLUTION OF PAYMENT SYSTEMS: THE US MEDICAID PROGRAM	536
BACKGROUND	536
CHOICE OF MEDICAID BENEFITS VERSUS SELF-INSURANCE VERSUS PRIVATE INSURANCE	538
EMPIRICAL EVIDENCE ON MEDICAID FEE SCHEDULES	542
MEDICAID AND NURSING HOME CARE	543
12.5 EVOLUTION OF PAYMENT SYSTEMS: CANADA'S MEDICARE	544
BACKGROUND	544
EFFECTS OF THE CANADIAN MEDICARE PROGRAM	546
Patient Waiting Time to Receipt of Care	546
Use of Costly Procedures	546
Disparities in Health and in the Use of Services	547
12.6 EVOLUTION OF PAYMENT SYSTEMS IN ASIAN COUNTRIES ON THE PACIFIC RIM	547
BACKGROUND	547
JAPAN	547
SOUTH KOREA	550
TAIWAN	552
EFFECTS OF UNIVERSAL HEALTH INSURANCE	553
12.7 DISCUSSION AND CONCLUSIONS	556
KEY CONCEPTS	558
REVIEW AND DISCUSSION QUESTIONS	558

EXERCISES	560
ONLINE SUPPLEMENTAL MATERIAL	563
SUPPLEMENTAL READINGS	563
REFERENCES	564
<b>CHAPTER 13 PUBLIC SUPPLY AND FINANCING</b>	<b>571</b>
13.1 THE RATIONALE FOR PUBLIC PROVISION OF HEALTH CARE	572
THE ROLE OF TRANSACTION COSTS	572
NONCONTRACTIBLE OUTCOMES REVISITED	573
REDISTRIBUTIVE CONCERNS	577
13.2 PUBLIC PROVISION IN HIGH-INCOME COUNTRIES IN PRACTICE	580
THE UNITED KINGDOM'S NATIONAL HEALTH SERVICE	580
Overview	580
Rationing by Queues Rather Than by Prices	581
Nonprice Rationing: Pros and Cons	582
Empirical Evidence on the Costs of Waiting Lists	587
The NHS Internal Market	591
COMPETITION AMONG PUBLIC SECTOR HOSPITALS: A REEXAMINATION OF ITS EFFECTS	591
AUSTRALIA	593
Overview	593
Empirical Evidence	595
13.3 PUBLIC PROVISION OF PERSONAL HEALTH CARE SERVICES IN OTHER COUNTRIES	596
HIGH-INCOME COUNTRIES	596
MIDDLE- AND LOW-INCOME COUNTRIES	596
Dominance of Public Ownership Form	596
Evidence on Quality of Care	597
Public Policy Options for Improving Quality of Care	599
Empirical Evidence on Effects of Interventions to Improve Quality of Care	600
13.4 THE EVOLUTION OF CHINA'S HEALTH CARE SYSTEM	602
PREREFORM PERIOD (1950–1978)	602
THE FIRST PERIOD OF REFORM (1978–2002)	602
THE SECOND PERIOD OF REFORM (2003–2012)	605
THE LATEST HEALTH SYSTEM REFORM: 2013 AND AFTERWARD	612

	13.5 EVALUATION AND COMPARISON OF HEALTH CARE SYSTEMS	613
	COMPARISONS BASED ON INTERMEDIATE PERFORMANCE MEASURES	614
	Access	614
	Cost	616
	Quality	618
	COMPARISONS BASED ON TWO PERFORMANCE GOALS	619
	Efficiency	619
	Equity	620
	13.6 SUMMARY	622
	KEY CONCEPTS	624
	REVIEW AND DISCUSSION QUESTIONS	625
	EXERCISES	626
	ONLINE SUPPLEMENTAL MATERIAL	628
	SUPPLEMENTAL READINGS	628
	REFERENCES	629
<b>PART IV</b>	<b>PERFORMANCE OF THE HEALTH CARE SECTOR: POSITIVE AND NORMATIVE ASPECTS</b>	<b>635</b>
<b>CHAPTER 14</b>	<b>COST AND COST-EFFECTIVENESS ANALYSIS</b>	<b>637</b>
	14.1 OVERVIEW OF COST-EFFECTIVENESS AND COST-BENEFIT ANALYSIS	638
	14.2 COST-EFFECTIVENESS ANALYSIS: MEASURING COST	642
	OVERVIEW	642
	CONCEPT OF OPPORTUNITY COST	642
	DIRECT AND INDIRECT COSTS	643
	OTHER COST CONCEPTS	644
	Transfer Costs	644
	Future Costs	644
	Sunk versus Incremental Costs	645
	Joint Costs/Joint Production	645
	Cost from Alternative Perspectives	646
	14.3 COST-EFFECTIVENESS ANALYSIS: MEASURING EFFECTIVENESS	647
	EFFECTIVENESS VERSUS EFFICACY	647



ENDPOINTS	648
EVALUATING THE MARGINAL EFFECT OF SPECIFIC TECHNOLOGIES	653
Goal of Evaluation	653
Transition Probabilities	653
Markov Chains	654
Obtaining Transition Probabilities from Observational Data	654
DISCOUNTING	656
Rationale for Discounting	656
DETERMINING THE APPROPRIATE DISCOUNT RATE: FINANCIAL VERSUS HEALTH DISCOUNT RATES	657
COMPUTING A COST-EFFECTIVENESS RATIO	659
14.4 APPLICATIONS OF COST-EFFECTIVENESS ANALYSIS	660
DISEASE PREVENTION	660
THE EXPERIENCE OF A US STATE, OREGON	660
COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION	661
COST-EFFECTIVENESS OF HIV TREATMENT IN LOW-INCOME SETTINGS	663
COST-EFFECTIVENESS OF SCREENING FOR CERVICAL CANCER IN LOW-INCOME SETTINGS	668
14.5 USE OF ECONOMIC EVALUATION IN PRACTICE: CONCLUSIONS AND IMPLICATIONS	670
KEY CONCEPTS	672
REVIEW AND DISCUSSION QUESTIONS	672
EXERCISES	673
ONLINE SUPPLEMENTAL MATERIAL	675
SUPPLEMENTAL READINGS	675
REFERENCES	675
<b>CHAPTER 15</b> <b>MEASURING BENEFITS AND COST-BENEFIT ANALYSIS</b>	<b>679</b>
15.1 MEASURING BENEFITS IN COST-BENEFIT ANALYSIS: A REVIEW	680
15.2 THE REVEALED PREFERENCE APPROACH	682
OBJECTIVE	682
UNDERLYING ASSUMPTIONS	683
EVIDENCE FROM LABOR MARKETS	683
VALUE OF A STATISTICAL LIFE	687

AN APPLICATION OF THE REVEALED PREFERENCE APPROACH: CIGARETTE SMOKERS AS JOB RISK TAKERS	688
15.3 THE STATED PREFERENCE APPROACH	691
CONTINGENT VALUATION	692
Stated Choice or Attribute-Based Methods	693
Contingent Behavior or Contingent Activity Questions	693
Assessing the Validity of Stated Preference Measures	694
STATED PREFERENCE METHOD APPLICATION 1	694
STATED PREFERENCE METHOD APPLICATION 2	696
Theory: Risk-Dollar Trade-offs	697
Theory: Risk-Risk Trade-offs	697
Surveys of WTP to Avoid Intangible Loss of Multiple Sclerosis	697
Results	699
Implications	700
STATED PREFERENCE APPLICATION 3: BENEFITS AND COSTS OF CHOLERA VACCINATION	701
Background and Study Rationale	701
Program Benefit and Cost	702
Measuring Private Benefit to the Vaccinated	702
Use of Stated Preference Method to Measure Vaccine Demand	704
Measuring Private Benefit to the Unvaccinated	704
Measuring Savings in Public Health Expenditures Attributable to the Vaccine Program	704
Some Key Findings	704
15.4 USE OF COST-BENEFIT AND COST-EFFECTIVENESS ANALYSIS IN PUBLIC DECISION MAKING	705
15.5 CONCLUSION	708
KEY CONCEPTS	709
REVIEW AND DISCUSSION QUESTIONS	709
EXERCISES	710
ONLINE SUPPLEMENTAL MATERIAL	712
SUPPLEMENTAL READINGS	712
REFERENCES	712

<b>CHAPTER 16</b>	<b>THE CONTRIBUTION OF PERSONAL HEALTH SERVICES TO LONGEVITY, POPULATION HEALTH, AND ECONOMIC GROWTH</b>	<b>715</b>
16.1	THE LINK BETWEEN HEALTH AND ECONOMIC SECTORS	716
	OVERVIEW	716
	RELATIONSHIPS AMONG PROVISION OF PERSONAL HEALTH CARE SERVICES, IMPROVED HEALTH AND LONGEVITY, AND ECONOMIC GROWTH	719
16.2	EFFECTS OF HEALTH CARE FINANCING ON NATIONAL ECONOMIES	721
	SAVING BEHAVIOR	721
	LABOR MARKET OUTCOMES	722
	WELFARE LOSS OF TAXATION	724
16.3	SECULAR TRENDS IN DETERMINANTS OF HEALTH INPUTS AND OUTPUTS	727
	SECULAR TRENDS IN EXPENDITURES ON PERSONAL HEALTH CARE SERVICES	727
	DETERMINANTS OF PERSONAL HEALTH CARE EXPENDITURES	727
	SECULAR TRENDS IN HEALTH OUTCOMES	730
	DETERMINANTS OF MORTALITY	732
16.4	CONTRIBUTIONS OF PERSONAL HEALTH CARE SERVICES TO IMPROVED POPULATION HEALTH	733
	CONCEPTUAL FRAMEWORK	733
	EMPIRICAL EVIDENCE FROM CROSS-SECTIONAL STUDIES	735
	OVERVIEW OF ANALYTIC APPROACHES	736
	THE DISEASE APPROACH	738
	THE PROXY VARIABLE APPROACH	740
	THE ACCOUNTING METHOD	742
16.5	CONTRIBUTION OF IMPROVED HEALTH TO ECONOMIC GROWTH	743
	DIRECT EFFECT ON PRODUCTIVITY	743
	INDIRECT EFFECTS OPERATING THROUGH FERTILITY, EDUCATION, AND SAVING	744
	OTHER INDIRECT EFFECTS	745
	CONTESTED ISSUES	746
16.6	THE HEALTH SECTOR AS A JOB MACHINE	748
16.7	ECONOMIC GROWTH AND DISEASE PATTERNS	749
16.8	SUMMARY AND CONCLUSIONS	750
	KEY CONCEPTS	751
	REVIEW AND DISCUSSION QUESTIONS	752

	EXERCISES	753
	ONLINE SUPPLEMENTAL MATERIAL	754
	SUPPLEMENTAL READINGS	755
	REFERENCES	755
<b>CHAPTER 17</b>	<b>FRONTIERS OF HEALTH ECONOMICS</b>	<b>759</b>
	17.1 RATIONAL VERSUS IRRATIONAL DECISION MAKING IN HEALTH CARE	759
	17.2 INFORMATION, ASYMMETRIC INFORMATION, AND ITS EFFECTS	762
	HOW PEOPLE OBTAIN INFORMATION	762
	17.3 INDUSTRIAL ORGANIZATION OF THE HEALTH CARE SECTOR	765
	PRINCIPAL-AGENT ISSUES: PHYSICIANS	765
	PAY FOR PERFORMANCE	766
	COMPETITION AMONG HOSPITALS	767
	COMPETITION VERSUS PUBLIC REGULATION VERSUS PUBLIC OWNERSHIP IN HEALTH CARE	768
	CLINICAL DECISION MAKING	769
	17.4 FINAL WORD	770
	KEY CONCEPTS	770
	REVIEW AND DISCUSSION QUESTIONS	771
	SUPPLEMENTAL READINGS	772
	REFERENCES	772
	INDEX	775